ArticleInternational journal of general medicine2026
Tamoxifen Combined with Hormone Replacement in Women with Thin Endometrium Receiving Frozen-Thawed Embryo Transfer for Promoting Endometrial Growth: A Double-Blinded, Randomized Controlled Trial.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04292886 (Hormone Replacement Versus Tamoxifen Combined Of Hormone Replacement in Women With a Thin Endometrium Undergoing Frozen-thawed Embryo Transfer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hormone Replacement Versus Tamoxifen Combined Of Hormone Replacement in Women With a Thin Endometrium Undergoing Frozen-thawed Embryo Transfer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thin endometrium continues to pose a significant challenge in assisted reproductive technology (ART) cycles, necessitating further exploration of therapeutic approaches. Tamoxifen (TMXF) has been primarily used in ovarian stimulation therapy and can also be implemented as an endometrial preparation protocol, potentially improving endometrial thickness. Does TMXF combined with hormone replacement therapy (HRT) in women with thin endometrium receiving frozen-thawed embryo transfer (FET) improve the endometrial thickness and pregnancy outcome compared to hormone replacement alone? Methods: This single-centre prospective double-blind randomized controlled trial ran between March 2020 and October 2022. In it, 120 patients with thin endometrium were randomized to TMXF-HRT and control HRT groups at a 1:1 ratio. The primary outcome was endometrium thickness. The secondary outcomes include embryo implantation rate, miscarriage rate and live birth rate. This trial is registered at the ClinicalTrials.gov, number NCT04292886 (Registration Date: March 1, 2020). Results: Endometrial thickness was significantly greater in the TMXF-HRT group than in the HRT alone group (7.80 ± 0.93 vs 6.93 ± 0.80 mm, P < 0.001), and multivariate analysis confirmed a positive effect of TMXF supplementation on endometrial thickness. However, no significant differences were observed between the two groups in embryo implantation rate or live birth rate. Conclusion: TMXF combined with HRT can significantly increase endometrial thickness and has the potential to improve clinical pregnancy outcomes (the difference was not statistically significant).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.